Epitalon / Epithalon – AEDG Tetrapeptide

An AEDG tetrapeptide discussed in aging, telomere, and circadian research.

By

Peptide Dosing Library
Research & Education

Last reviewed

October 2026

5 mg/day

Reported Short Course A

10 mg/day

Reported Short Course B

20 Days

First Reported Course Duration

10 Days

Second Reported Course Duration
Epitalon (Epithalon)

Epitalon / Epithalon

Leave blank if no affiliate links are used. If affiliate links are added, disclose the relationship clearly.

OVERVIEW

Understanding Epitalon

Epitalon is an AEDG tetrapeptide discussed in aging, telomere, and circadian research. The source distinguishes older research programmes and community cycles from a large blinded human injection trial, which it does not identify.

Peptide Type

AEDG tetrapeptide

Research Areas

Aging, telomere, and circadian research

Reported Administration Route

Subcutaneous (SC)

Reported Short Course A

5 mg/day for 20 days

Reported Short Course B

10 mg/day for 10 days

Reported Repeat Frequency

Two or three times per year; quick-start text instead says one or two times per year.

Important Research Limitation

These inconsistent community conventions are not a proven human telomere regimen. Epitalon should not be confused with related extracts.

REPORTED PROTOCOLS

Reported Epitalon Schedules

The source describes two reported short-course schedules and inconsistent repeat-frequency conventions. These are reported examples, not established human treatment guidance.

SC example

Per administration

Frequency

Daily total

Reported cycle

Reported Short Course A

5 mg
Daily
5 mg/day
20 days

Reported Short Course B

10 mg
Daily
10 mg/day
10 days

Repeat Frequency

Not specified in source
Not specified in source
Not specified in source
Two or three times/year; quick-start text says one or two times/year.

Reported Short Course A

Per administration

5 mg

Frequency

Daily

Daily total

5 mg/day

Reported cycle

20 days

Reported Short Course B

Per administration

10 mg

Frequency

Daily

Daily total

10 mg/day

Reported cycle

10 days

Repeat Frequency

Per administration

Not specified in source

Frequency

Not specified in source

Daily total

Not specified in source

Reported cycle

Two or three times/year; quick-start text says one or two times/year.
The source reports inconsistent repeat-frequency conventions. These schedules are not a proven human telomere regimen.

Reported Use Does Not Establish Efficacy

The source does not identify a large blinded human injection trial establishing Epitalon benefits. Community schedules should not be interpreted as clinically validated regimens.

SAFETY

Safety & Research Limitations

Human safety and efficacy information is limited. Telomere findings do not establish lifespan extension.

Important Research Concerns

Important Cautions

HANDLING & STORAGE

Storage & Handling Information

Powder Storage

Source recommends storage at -20°C.

Mixed Product Storage

Keep refrigerated and protected from light.

Monitoring Considerations

Sleep and circadian observations.

Product Identification

Distinguish Epitalon from related extracts.

CONCENTRATION WORKSHEET

Epitalon Concentration Calculator

Example calculation values from the source. These are not mixing or administration instructions.

Amount (mg)

Final volume (mL)

Concentration (mg/mL)

Per 1 U (mcg)

Per 10 U (mcg)

10

2
5
50
500

50

5
10
100
1000

Amount (mg)

10

Final volume (mL)

2

Concentration (mg/mL)

5

Per 1 U (mcg)

50

Per 10 U (mcg)

500

Amount (mg)

50

Final volume (mL)

5

Concentration (mg/mL)

10

Per 1 U (mcg)

100

Per 10 U (mcg)

1000
U means a U-100 volume marking: 1 U = 0.01 mL. For a blend, total mass is not the amount of each ingredient. Separate-component arithmetic remains separate. These inputs are examples, not mixing or administration instructions.

CLINICAL EVIDENCE

What the Research Shows

Mortality findings often concern epithalamin extract, sometimes with thymalin, rather than isolated synthetic AEDG. No large blinded injection trial establishes Epitalon longevity benefit.

01

Extract-Specific Findings

Mortality findings often concern epithalamin extract rather than isolated synthetic AEDG.

02

Related Peptide Combinations

Some findings involve epithalamin used with thymalin.

03

Limited Human Injection Evidence

No large blinded human injection trial establishes Epitalon longevity benefit.

REGULATORY INFORMATION

Regulatory & Research Status

Regulatory Status Not Specified

The source does not provide a verified current regulatory status for Epitalon / Epithalon.
No current regulatory approval details are specified in the source.